<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04920903</url>
  </required_header>
  <id_info>
    <org_study_id>COR588</org_study_id>
    <nct_id>NCT04920903</nct_id>
  </id_info>
  <brief_title>A Single and Multiple Ascending Dose Study of COR588</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First-in-Human, Single- and Multiple-Ascending Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Oral COR588 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cortexyme Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cortexyme Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a randomized, double-blind, placebo-controlled, single and multiple ascending&#xD;
      dose study to assess the safety and tolerability of COR588 HCl in healthy male and female&#xD;
      subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 26, 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events.</measure>
    <time_frame>Through Day 8 for the single ascending dose phase and through Day 19 for the multiple ascending dose phase.</time_frame>
    <description>Assessment of the incidence and severity of treatment-emergent adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in chemistry lab measures (Sodium [Na], Blood Urea Nitrogen [BUN], Calcium [Ca], Total bilirubin).</measure>
    <time_frame>Through Day 8 for the single ascending dose phase and through Day 19 for the multiple ascending dose phase.</time_frame>
    <description>Assessment of changes in serum chemistry measures.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in hematology lab measures (red blood cell count [RBC], hemoglobin [Hgb], hematocrit [Hct]).</measure>
    <time_frame>Through Day 8 for the single ascending dose phase and through Day 19 for the multiple ascending dose phase.</time_frame>
    <description>Assessment of changes in hematology measures.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in urinalysis lab parameters (pH, specific gravity, glucose).</measure>
    <time_frame>Through Day 8 for the single ascending dose phase and through Day 19 for the multiple ascending dose phase.</time_frame>
    <description>Assessment of changes in urinalysis parameters.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>To Day 3 for the single ascending dose phase and to Day 11 for the multiple ascending dose phase.</time_frame>
    <description>Area under the concentration-time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>To Day 3 for the single ascending dose phase and to Day 11 for the multiple ascending dose phase.</time_frame>
    <description>Maximum observed drug concentration during a dosing interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>To Day 3 for the single ascending dose phase and to Day 11 for the multiple ascending dose phase.</time_frame>
    <description>Time to Cmax</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>COR588</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COR588</intervention_name>
    <description>Increasing doses of COR588 will be administered for cohorts 1-4 in the single ascending dose phase and for cohorts 1-4 in the multiple ascending dose phase.</description>
    <arm_group_label>COR588</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered for cohorts 1-4 in the single ascending dose phase and for cohorts 1-4 in the multiple ascending dose phase.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male and female subjects between 18 to 55 years of age, inclusive (at the time&#xD;
             of consent) for Part A;&#xD;
&#xD;
          -  Body mass index between 18 and 32 kg/m2, inclusive, at screening and Day -1;&#xD;
&#xD;
          -  Participants with no clinically significant abnormal screening results in the opinion&#xD;
             of the investigator;&#xD;
&#xD;
          -  All screening laboratory parameters (chemistry, hematology, coagulation, urinalysis)&#xD;
             within normal limits or considered not clinically significant in the opinion of the&#xD;
             investigator. If necessary, in the investigator's opinion, screening labs may be&#xD;
             repeated once to confirm the results if error is suspected.&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must have a negative blood or urine pregnancy&#xD;
             test within 24 hours prior to the start of investigational product and must not be&#xD;
             breastfeeding, lactating or planning pregnancy during the study period. WOCBP must&#xD;
             agree to use an acceptable form of contraception during the treatment period and for&#xD;
             at least 30 days after the last dose of investigational product.&#xD;
&#xD;
          -  A male subject with a female partner of childbearing potential is eligible to&#xD;
             participate if he agrees to use acceptable contraception during the treatment period&#xD;
             and for at least 90 days after the last dose of study treatment and refrains from&#xD;
             donating sperm during this period;&#xD;
&#xD;
          -  Agree to comply with study-specified diet and consume the high-fat breakfast in its&#xD;
             entirety (food effect cohort) while confined in the study site;&#xD;
&#xD;
          -  Provide signed informed consent prior to any study procedures commencing, understand&#xD;
             and comply with the requirements of the study, and be able to communicate with the&#xD;
             investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of significant neurological, cardiovascular, hematological, psychiatric,&#xD;
             hepatic, gastrointestinal, pulmonary, endocrine, immunologic or renal disease;&#xD;
&#xD;
          -  History or presence of malignancy within the past 2 years prior to Day -1 with the&#xD;
             exception of adequately treated basal cell or squamous cell carcinoma of the skin;&#xD;
&#xD;
          -  History of conditions (e.g., chronic diarrhea or prior abdominal surgery) known to&#xD;
             interfere with the absorption, distribution, metabolism, or excretion of drugs;&#xD;
&#xD;
          -  Clinically significant acute illness or infection within 14 days prior to Day -1;&#xD;
&#xD;
          -  Any surgical procedure within 3 months prior to Day -1, that may interfere with the&#xD;
             performance in the study in the judgment of the investigator;&#xD;
&#xD;
          -  History or presence of cardiac abnormalities or congenital long QT syndrome;&#xD;
&#xD;
          -  Subjects with a QTcF interval &gt;450 msec for males and &gt;470 msec for females at&#xD;
             screening or Day -1;&#xD;
&#xD;
          -  Any dietary restriction, intolerance, or food allergy that would prohibit the&#xD;
             consumption of a high fat breakfast (food effect cohort only);&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Joanna Bolger, MS</last_name>
    <phone>1-858-248-5124</phone>
    <email>jbolger@cortexyme.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vladimir Skljarevski, MD</last_name>
    <phone>1-317-985-2428</phone>
    <email>vskljarevski@cortexyme.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nucleus Network Pty Ltd</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip Ryan, MD</last_name>
      <phone>0438009787</phone>
      <email>p.ryan@nucleusnetwork.com.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 4, 2021</study_first_submitted>
  <study_first_submitted_qc>June 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2021</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

